A high-stakes legal fight between Regeneron and Amgen over the blockbuster eye drug Eylea is putting the U.S. patent system ...

(NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult patients with relapsed or refractory ...

New enzyme discovery offers hope for millions of diabetes patients The scientists also ran molecular dynamics simulations to observe how the enzyme moves and reacts under different conditions.

CD38 is a signaling enzyme responsible for catalyzing the synthesis of cyclic ADP ribose (cADPR) and nicotinic acid adenine dinucleotide phosphate; both are universal Ca2+ messenger molecules.

2.4 CD38 enzyme activity and therapeutic antibodies: potential influence on refractoriness A crucial question is whether the binding of therapeutic CD38 antibodies interferes with the enzyme’s ...

On day 1029, a polyspecific PF4–polyanion enzyme-linked immunosorbent assay (ELISA) was strongly positive, but corresponding positive results on a platelet-activation assay were atypical for HIT.

Background and purpose: Vascular dementia (VaD) is one of the most common causes of cognitive decline, primarily resulting from cerebrovascular damage. Central to the pathogenesis of VaD are ...

The literature describing the CD38 regulation of NICD originate from pre-clinical models of tissue damage and infection where extracellular NAD+ concentrations are elevated. Although a similar ...

This manuscript describes soluble Uric Acid (sUA) as an endogenous inhibitor of CD38, affecting CD38 activity and NAD+ levels both in vitro and in vivo. Importantly, the inhibition constants ...

Using enzyme assays and in vitro and in vivo metabolic assays, we demonstrate that sUA directly inhibits the hydrolase and cyclase activities of CD38 via a reversible non-competitive mechanism, ...

CD38 is an ecto-enzyme that degrades NAD and produces several byproducts including cyclic ADPR. We hypothesized that CD38 mediates pathological reductions in NAD levels contributing to PAH vascular ...

Antibody targeting CD38 enzyme shows positive impact in treating systemic sclerosis by Valerie Goodwin, University of Michigan Editors' notes ...